A Phase 3 interventional study of sitagliptin phosphate and Comparator: Diet in Diabetes Mellitus, Non-Insulin-Dependent, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-12.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 4th largest by enrollment of the 197 interventional ones that give a count, is one of 17 that started in 2007, is one of 74 in phase 3, and was the 37th registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Beijing Chao Yang Hospital · Sites in China
Ages 18–65
Bahria University · Sites in Pakistan
Ages 30–55
Yonsei University · Sites in Korea, Republic of
Ages 19–75
By country, each count listing its studies:
sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
198 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 11 · Phase 3 74 · Phase 4 68
First in 2003; this study’s year is marked. 17 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,512 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 102 across the 197 interventional studies. Of the 172 that completed or were terminated, 117 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
103 of 198 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 181 finished, 150 (83%) have results posted.
Among the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc, this one is the 6th largest by enrollment of the 170 interventional ones that give a count, is one of 19 that started in 2007, is one of 86 in phase 3, and was the 45th registered.
Merck & Co., Inc’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 181 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To compare the efficacy of three strategies of lifestyle changes associated with Januvia (sitagliptin) 100 mg/day in patients with Type 2 Diabetes Mellitus (T2DM) inadequately controlled by metformin (hemoglobin A1c [HbA1c] 6.5-9%). A difference between the three strategies of lifestyle changes was expected.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects received sitagliptin 100 mg once daily for 26 Weeks, and: No specific intervention (standard recommendation) on physical exercise and diet.
Drug: sitagliptin phosphate
Subjects received sitagliptin 100 mg once daily for 26 Weeks, and: Intervention on diet which includes advice on diet with a leaflet and a diary
Drug: sitagliptin phosphate · Behavioral: Comparator: Diet
Subjects received sitagliptin 100 mg once daily for 26 Weeks, and: Intervention on diet + physical activity which includes advice on diet and physical activity with leaflets and diaries PLUS advice on physical activity with the utilization of a pedometer: subjects were asked to walk 10,000 steps per day 5 or more days per week.
Drug: sitagliptin phosphate · Behavioral: Comparator: Diet · Behavioral: Comparator: Physical Activity
sitagliptin 100 mg once daily. Duration of treatment: 26 Weeks
Diet
Physical Activity
Hemoglobin A1c Measurement
Hemoglobin A1c (HbA1c) is a measure of glycated hemoglobin in the blood. HbA1c greater than 6.5% was considered inadequately controlled.
Time frame: Baseline and Week 24
Fasting Plasma Glucose (FPG) Measurement
Generally FPG values of \~5.0-7.2 mmol/L would be considered goal (American Diabetes Association).
Time frame: Baseline and Week 24
| Milestone | Sitagliptin With Standard of Care | Sitagliptin With Diet Advice | Sitagliptin With Diet and Physical Activity Advice |
|---|---|---|---|
| Started | 412 | 414 | 306 |
| Completed | 333 | 334 | 250 |
| Not completed | 79 | 80 | 56 |
| Withdrew: Only one reason for discontinuation | 62 | 61 | 48 |
| Withdrew: Two or more reasons for discontinuation | 17 | 19 | 8 |
Hemoglobin A1c (HbA1c) is a measure of glycated hemoglobin in the blood. HbA1c greater than 6.5% was considered inadequately controlled.
| percent HbA1c | Sitagliptin With Standard of Care | Sitagliptin With Diet Advice | Sitagliptin With Diet and Physical Activity Advice |
|---|---|---|---|
| Baseline (n=360, 358, and 265, respectively) | 7.37 ± 0.61 | 7.50 ± 0.66 | 7.49 ± 0.60 |
| Week 24 (n=362, 358, and 265, respectively) | 7.33 ± 1.09 | 7.42 ± 1.15 | 7.40 ± 1.07 |
Generally FPG values of \~5.0-7.2 mmol/L would be considered goal (American Diabetes Association).
| mmol/L glucose | Sitagliptin With Standard of Care | Sitagliptin With Diet Advice | Sitagliptin With Diet and Physical Activity Advice |
|---|---|---|---|
| Baseline (n=350, 350, 252, respectively) | 8.87 ± 1.98 | 9.00 ± 2.03 | 8.91 ± 1.87 |
| Week 24 (n=310, 303, and 224, respectively) | 8.21 ± 2.07 | 8.32 ± 2.08 | 8.47 ± 2.17 |
Collected over This safety data includes AEs and SAEs that occurred during treatment (Visit 2 to Visit 4).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sitagliptin With Standard of Care | — | 8/412 (1.9%) | 0/412 (0%) |
| Sitagliptin With Diet Advice | — | 18/414 (4.3%) | 0/414 (0%) |
| Sitagliptin With Diet and Physical Activity Advice | — | 7/305 (2.3%) | 0/305 (0%) |
| Event | Sitagliptin With Standard of Care | Sitagliptin With Diet Advice | Sitagliptin With Diet and Physical Activity Advice |
|---|---|---|---|
| PROSTATE CANCERNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/412 | 0/414 | 2/305 |
| FRACTUREInjury, poisoning and procedural complications | 0/412 | 0/414 | 1/305 |
| OSTEOARTHRITISMusculoskeletal and connective tissue disorders | 0/412 | 0/414 | 1/305 |
| LUNG NEOPLASM MALIGNANTNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/412 | 0/414 | 1/305 |
| CERVICAL ROOT PAINNervous system disorders | 0/412 | 0/414 | 1/305 |
| SCIATICANervous system disorders | 0/412 | 0/414 | 1/305 |
| IDIOPATHIC THROMBOCYTOPENIC PURPURABlood and lymphatic system disorders | 1/412 | 0/414 | 0/305 |
| ACUTE CORONARY SYNDROMECardiac disorders | 1/412 | 1/414 | 0/305 |
| ADAMS-STOKES SYNDROMECardiac disorders | 1/412 | 0/414 | 0/305 |
| INGUINAL HERNIAGastrointestinal disorders | 1/412 | 0/414 | 0/305 |
| Age, Continuous(years) | Sitagliptin With Standard of Care | Sitagliptin With Diet Advice | Sitagliptin With Diet and Physical Activity Advice | Total |
|---|---|---|---|---|
| Mean | 58.26 ± 10.04 | 57.47 ± 9.12 | 57.30 ± 9.90 | 57.71 ± 9.68 |
| Sex: Female, Male(Participants) | Sitagliptin With Standard of Care | Sitagliptin With Diet Advice | Sitagliptin With Diet and Physical Activity Advice | Total |
|---|---|---|---|---|
| Female | 181 | 175 | 126 | 482 |
| Male | 181 | 183 | 139 | 503 |
No study locations are listed for this record.
Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php
No publications or documents are linked to this record.
Ran from Apr 2007 to primary completion in Nov 2009, 31 months.
Results were first posted in May 2011, 1 year 5 months after primary completion. A results delay was requested in Nov 2010.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 31 months is above that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sitagliptin